Insider Buying: Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $177,171.20 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director George Pavlov acquired 9,920 shares of the stock in a transaction that occurred on Friday, February 20th. The stock was purchased at an average price of $17.86 per share, for a total transaction of $177,171.20. Following the completion of the transaction, the director owned 25,000 shares in the company, valued at $446,500. The trade was a 65.78% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

George Pavlov also recently made the following trade(s):

• On Thursday, February 19th, George Pavlov acquired 4,422 shares of Maplight Therapeutics stock. The stock was purchased at an average cost of $17.57 per share, for a total transaction of $77,694.54.
• On Wednesday, February 18th, George Pavlov bought 10,658 shares of Maplight Therapeutics stock. The stock was purchased at an average price of $17.48 per share, with a total value of $186,301.84.

Maplight Therapeutics Trading Down 0.2%

Shares of NASDAQ:MPLT opened at $17.88 on Monday. Maplight Therapeutics, Inc. has a fifty-two week low of $12.24 and a fifty-two week high of $21.55. The company has a 50-day moving average price of $17.93. The stock has a market capitalization of $811.22 million and a P/E ratio of -0.48.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Morgan Stanley assumed coverage on Maplight Therapeutics in a report on Friday, November 21st. They set an “overweight” rating and a $34.00 price objective on the stock. Leerink Partners began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set an “outperform” rating and a $30.00 target price on the stock. Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. Stifel Nicolaus started coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set a “buy” rating and a $28.00 price objective on the stock. Finally, Jefferies Financial Group began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $32.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Maplight Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $31.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MPLT. Nuveen LLC acquired a new position in Maplight Therapeutics during the fourth quarter worth about $355,000. Deutsche Bank AG purchased a new position in shares of Maplight Therapeutics during the 4th quarter worth approximately $210,000. TD Asset Management Inc acquired a new position in shares of Maplight Therapeutics during the 4th quarter worth approximately $649,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Maplight Therapeutics in the 4th quarter valued at approximately $70,000. Finally, 5AM Venture Management LLC acquired a new stake in Maplight Therapeutics during the 4th quarter valued at $16,687,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.